Lesional characteristics and histopathology in paucibacillary leprosy patients with 2 or 3 skin lesions: Comparison between ROM and PB-MDT regimens

Indian Journal of Leprosy

Volumn 77, Issue 1, 2005, Pages 19-25

  Emmanuel, Margery ^a,c   Gupte, M D ^b  

^a TLMI   (India)

^b National Institute of Epidemiology   (India)

^c Schieffelin Leprosy Res/Train Ctr   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; LEPROSTATIC AGENT; MINOCYCLINE; OFLOXACIN; RIFAMPICIN;

ADULT; ARTICLE; CHILD; CLINICAL EXAMINATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PATIENT COMPLIANCE; PAUCIBACILLARY LEPROSY; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; SKIN BIOPSY; SKIN DEFECT; SKIN GRANULOMA;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; LEPROSTATIC AGENTS; LEPROSY; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MINOCYCLINE; OFLOXACIN; RIFAMPIN; SKIN;

EID: 17644400693     PISSN: 02549395     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (7)

1. Cree IA, McDougall AC, Coghill G et al (1985). Quantitation of the granuloma fraction in leprosy skin biopsies by planimetry. Int J Lepr Other Mycobact Dis 53: 582-6
2. Ebenezer GJ, Job CK (1999). Histopathological activity in paucibacillary leprosy patients after ROM therapy. Int J Lepr Other Mycobact Dis 67: 409-13
3. Gupte MD (1996). Presidential address at the XIX Biennial Conference of the Indian Association of Leprologists (15-17 December 1995, Pune). Indian J Lepr 68: 211-3
4. Ji B. Perani EG, Petinon C, Grosset JH (1992). Bacteriological activities of single or multiple doses of various combinations of new antileprosy drugs and/or rifampin against M. leprae in mice. Int J Lepr Other Mycobact Dis 60: 556-61
5. Levy L. Shepard CC, Fasal P (1976). The bactericidal effect of rifampicin on M. leprae in man: a) single doses of 600, 900 and 1200 mg and b) daily doses of 300 mg. Int J Lepr 44: 183-7
6. Single-Lesion Multicentre Trial Group (1997). Efficacy of single dose multidrug therapy for the treatment of single-lesion paucibacillary leprosy. Indian J Lepr 69: 121-9
7. -3 Lesion Multicentre Trial Group (2001). A comparative trial of single dose chemotherapy in paucibacillary leprosy patients with two to three skin lesions. Indian J Lepr 73: 131-43